A newly approved once-a-day pill helped clear a stubborn form of high cholesterol in trials

Regulators have approved a new once-daily tablet that sharply lowers the type of cholesterol most strongly tied to heart attacks and strokes, giving patients an oral option for a drug class that until now required injections. The medication, sold under the brand name Lipfendra and known generically as enlicitide, is the first pill in a family of therapies called PCSK9 inhibitors. In clinical trials it drove down low-density lipoprotein cholesterol by more than half, including in patients with an inherited condition that keeps their levels stubbornly high.

What PCSK9 inhibitors do in the body

PCSK9 is a protein that reduces the liver’s ability to clear low-density lipoprotein cholesterol, often called the bad cholesterol, from the bloodstream. It does so by breaking down the receptors on liver cells that pull that cholesterol out of circulation. When PCSK9 is blocked, those receptors survive longer, the liver removes more cholesterol, and blood levels fall.

Drugs that target this protein have existed for years, but they were available only as injections given every few weeks. The arrival of an oral version makes the mechanism accessible in the familiar form of a daily pill, a change that could broaden how many patients are willing and able to use it. Details of the approval and the drug’s labeling are summarized in the new-drug listings at drugs.com.

How the new pill differs from statins

Statins have long been the first line of defense against high cholesterol, and they remain widely used and inexpensive. But some patients do not reach their target levels on statins alone, cannot tolerate the side effects, or have inherited conditions that overwhelm what statins can accomplish. For those groups, additional tools have been limited, and the injectable PCSK9 inhibitors filled part of that gap.

The new oral inhibitor is taken as a 20-milligram tablet once a day, alongside a heart-healthy diet and exercise, and it can be layered on top of statin therapy. Because it works through a different mechanism than statins, the two can be combined to push cholesterol lower than either achieves alone, an approach that appeals to patients at the highest risk.

What the CORALreef trials measured

The approval rested on results from a clinical program known as the CORALreef trials, which tested the drug in different patient populations. In the study focused on general high cholesterol and a companion study in patients with an inherited form of the condition, the pill reduced low-density lipoprotein cholesterol by a placebo-adjusted 56 percent and 59 percent respectively at 24 weeks. Those reductions are substantial, cutting the harmful cholesterol well below what many patients achieve on standard therapy.

The inherited condition, heterozygous familial hypercholesterolemia, is the stubborn form that resists ordinary treatment because a genetic defect drives cholesterol production and blunts the body’s ability to clear it. The federal approval was announced by the Food and Drug Administration, which described the medication as the first oral PCSK9 inhibitor cleared to lower cholesterol in adults, in an announcement posted at fda.gov.

Who the drug is approved to treat

The medication is cleared as an addition to diet and exercise for adults with high cholesterol, including those with the inherited heterozygous form. It is aimed at people who need further reduction beyond what they get from statins or who require an alternative because of intolerance. That framing places it among the therapies reserved for higher-risk patients rather than as a routine first prescription.

As with any new medication, physicians weigh the drug against a patient’s overall risk profile, other prescriptions, and cost. The convenience of a daily pill removes one barrier that kept some patients away from the injectable versions, but decisions about starting it are made case by case with a prescribing clinician.

Cost and access are likely to shape how widely the pill is used. Branded PCSK9 inhibitors have historically carried high price tags and required insurer approval, and whether the oral version follows that pattern or reaches patients more affordably will influence its real-world impact. For people with the inherited condition, who often face very high cholesterol from a young age despite maximal standard treatment, even an expensive additional option can be significant, because their elevated risk begins early and compounds over a lifetime. Clinicians treating those patients have long sought therapies that work through mechanisms independent of statins, and an oral drug that fits into a daily routine may improve the odds that patients stay on treatment.

What questions remain about long-term benefit

While the trials clearly show the pill lowers cholesterol, analysts have noted that the data establishing whether that reduction translates into fewer heart attacks, strokes, and deaths over the long term is still developing. Cholesterol level is a well-validated stand-in for cardiovascular risk, but demonstrating hard outcomes typically requires larger and longer studies that follow patients for years.

That distinction is important for setting expectations. A drug that dramatically lowers a risk marker is promising, and the biology behind PCSK9 inhibition is well understood, but the full picture of its effect on cardiovascular events will come into focus as outcome studies mature. For now, the approval gives clinicians a powerful new oral tool for driving down cholesterol in patients who have long had few options beyond injections, marking a notable shift in how a stubborn condition can be treated.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview